![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Financial & competing interests disclosure
This work was supported by the Canadian Stem Cell Network, the Canadian Institutes for Health Research, the Leukemia and Lymphoma Society, the NIH (NCI 1R01CA157456), the Terry Fox Foundation, MaRS Innovation, the Ontario Institute of Cancer Research with funding provided by the Ontario Ministry of Research and Innovation, the Princess Margaret Hospital Foundation, and the Ministry of Long Term Health and Planning in the Province of Ontario. M Škrtic´holds a Canada Graduate Scholarship from the Canadian Institutes of Health Research. AD Schimmer is a Leukemia and Lymphoma Society Scholar in Clinical Research. M Škrtic´ and AD Schimmer are named as inventors on patent applications claiming the use of tigecycline for the treatment of hematologic malignancies. The authors are named as inventors on patent applications claiming the use of tigecycline for the treatment of leukemia. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.